Immunotoxins in cancer therapy.

Several antibodies have now been approved for the therapy of cancer. Two of these, rituximab (Rituxan) and alemtuzumab (CAMPATH; ILEX Oncology Inc), are capable of inducing cell death and tumor regressions when given alone. The third, trastuzumab (Herceptin), is not very effective by itself, but does potentiate the activity of paclitaxel (Taxol) and other chemotherapeutic agents. Unfortunately, most antibodies do not kill cancer cells unless they are armed with a cytotoxic agent, such as a radioisotope, a cytotoxic drug, or a protein toxin. Each of these have advantages and disadvantages.

[1]  Taylor Murray,et al.  Cancer statistics, 1998 , 1998, CA: a cancer journal for clinicians.

[2]  H. Gaudin,et al.  Localization of the diphtheria toxin receptor-binding domain to the carboxyl-terminal Mr approximately 6000 region of the toxin. , 1990, The Journal of biological chemistry.

[3]  R K Jain,et al.  Delivery of Molecular Medicine to Solid Tumors , 1996, Science.

[4]  W. Wilson,et al.  Responses in refractory hairy cell leukemia to a recombinant immunotoxin. , 1999, Blood.

[5]  M. Malmqvist,et al.  BIACORE: an affinity biosensor system for characterization of biomolecular interactions. , 1999, Biochemical Society transactions.

[6]  F. Uckun,et al.  Production of recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system for biotherapy of GMCSF-receptor positive hematologic malignancies. , 1998, Protein expression and purification.

[7]  M. Ratain,et al.  Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. , 1998, Blood.

[8]  I. Pastan,et al.  Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor. , 1995, The Biochemical journal.

[9]  D. Esseltine,et al.  Clinical trials with blocked ricin immunotoxins. , 1998, Current topics in microbiology and immunology.

[10]  E. Vitetta,et al.  An in vivo model to study immunotoxin-induced vascular leak in human tissue. , 1999, Journal of immunotherapy.

[11]  E. Vitetta,et al.  Vascular leak syndrome: a side effect of immunotherapy. , 1997, Immunopharmacology.

[12]  F. Foss,et al.  Diphtheria toxin fusion proteins. , 1998, Current topics in microbiology and immunology.

[13]  I. Pastan,et al.  A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. , 1992, Analytical biochemistry.

[14]  Kendall A. Smith,et al.  Interleukin 2 receptor‐targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin‐related interleukin 2 fusion protein into cells , 1990, European journal of immunology.

[15]  I. Pastan,et al.  Complete regression of human B‐cell lymphoma xenografts in mice treated with recombinant anti‐CD22 immunotoxin RFB4(dsFv)‐PE38 at doses tolerated by cynomolgus monkeys , 1999, International journal of cancer.

[16]  R. Scheuermann,et al.  CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. , 1995, Leukemia & lymphoma.

[17]  I. Pastan,et al.  Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli , 1987, Cell.

[18]  E. Oldfield,et al.  Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors , 1997, Nature Medicine.

[19]  I. Pastan,et al.  Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: targeting with a single chain antibody variable domain isolated by phage display. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Tsuyoshi Uchida,et al.  Reconstitution of Diphtheria Toxin from Two Nontoxic Cross-Reacting Mutant Proteins , 1972, Science.

[21]  T. Waldmann,et al.  The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[22]  K. Hellström,et al.  In vitro and in vivo characterization of BR96 sFv-PE40. A single-chain immunotoxin fusion protein that cures human breast carcinoma xenografts in athymic mice and rats. , 1994, Journal of immunology.

[23]  S. O’Day,et al.  Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  I. Pastan,et al.  Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells. , 1997, Blood.

[25]  I. Pastan,et al.  Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol. , 1990, The Journal of biological chemistry.

[26]  M. Willingham,et al.  Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells. , 1996, Cancer research.

[27]  K. Tsurugi,et al.  The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxins. , 1987, The Journal of biological chemistry.

[28]  D. Mckay,et al.  Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[29]  I. Pastan,et al.  Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  J. Uhr,et al.  Large scale preparation of an immunoconjugate constructed with human recombinant CD4 and deglycosylated ricin A chain. , 1990, Journal of immunological methods.

[31]  J. Taylor,et al.  Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. Youle,et al.  Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. , 1987, Science.

[33]  M. Tsudo,et al.  Interleukin‐2 Receptor β‐Chain (p70–75) Expressed on Leukemic Cells from Adult T Cell Leukemia Patients , 1990, Japanese journal of cancer research : Gann.

[34]  K. Tsurugi,et al.  Mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. , 1986, Nucleic acids symposium series.

[35]  V. Diehl,et al.  Immunotoxins constructed with anti‐CD25 monoclonal antibodies and deglycosylated ricin a‐chain have potent anti‐tumour effects against human hodgkin cells in vitro and solid hodgkin tumours in mice , 1991, International journal of cancer.

[36]  A. Finkelstein,et al.  Roles of Glu 349 and Asp 352 in membrane insertion and translocation by diphtheria toxin , 1996, Protein science : a publication of the Protein Society.

[37]  Russo,et al.  Phase I Clinical Study of the Recombinant Oncotoxin TP4O in Superficial Bladder Cancer , 2005 .

[38]  R. Collier,et al.  Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin. , 1987, The Journal of biological chemistry.

[39]  D. Liggitt,et al.  Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  J. Rizo,et al.  Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  I. Pastan,et al.  Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  I. Pastan,et al.  Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma. , 1995, Cancer research.

[43]  T. Strom,et al.  Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells. , 1990, The Journal of biological chemistry.

[44]  N. Oppenheimer-Marks,et al.  Ricin A-chain and ricin A-chain immunotoxins rapidly damage human endothelial cells: implications for vascular leak syndrome. , 1993, Experimental cell research.

[45]  I. Pastan,et al.  Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. , 1996, Bone marrow transplantation.

[46]  H. P. Fell,et al.  Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[47]  S. Steinberg,et al.  Continuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I study. , 1995, Blood.

[48]  I. Pastan,et al.  Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma , 1994 .

[49]  I. Pastan,et al.  Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol. , 1992, The Journal of biological chemistry.

[50]  V. Chaudhary,et al.  Characterization of a cellular protease that cleaves Pseudomonas exotoxin , 1992, Infection and immunity.

[51]  J. Murphy,et al.  An intact transmembrane helix 9 is essential for the efficient delivery of the diphtheria toxin catalytic domain to the cytosol of target cells. , 1994, The Journal of biological chemistry.

[52]  A. Hagenbeek,et al.  Treatment of acute myelocytic leukemia with interleukin-6 Pseudomonas exotoxin fusion protein in a rat leukemia model. , 1996, Leukemia.

[53]  H. DeVroom,et al.  Intraventricular immunotoxin therapy for leptomeningeal neoplasia. , 1997, Neurosurgery.

[54]  D. Milford,et al.  Comparison of ribosome-inactivating proteins in the induction of apoptosis. , 1997, Toxicology letters.

[55]  M. Chiron,et al.  Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver. , 1994, The Journal of biological chemistry.

[56]  J. Mindell,et al.  Membrane translocation and channel-forming activities of diphtheria toxin are blocked by replacing isoleucine 364 with lysine , 1993, Infection and immunity.

[57]  T. Uchida,et al.  Diphtheria toxin and related proteins. I. Isolation and properties of mutant proteins serologically related to diphtheria toxin. , 1973, The Journal of biological chemistry.

[58]  R. Collins,et al.  A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. , 1993, Blood.

[59]  I. Pastan,et al.  Targeting Pseudomonas exotoxin to hematologic malignancies. , 1995, Seminars in cancer biology.

[60]  R. Kreitman,et al.  An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. , 1997, Biochemistry.

[61]  A. Frankel.  Clinical Applications of Immunotoxins , 1998, Current Topics in Microbiology and Immunology.

[62]  P. Hall,et al.  DT388-GM-CSF, a novel fusion toxin consisting of a truncated diphtheria toxin fused to human granulocyte–macrophage colony-stimulating factor, prolongs host survival in a SCID mouse model of acute myeloid leukemia , 1999, Leukemia.

[63]  T. Strom,et al.  Cytotoxicity of interleukin 2-toxin toward lymphocytes from patients with adult T-cell leukemia. , 1989, Cancer research.

[64]  T. Mitamura,et al.  Heparin‐binding EGF‐like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up‐regulates functional receptors and diphtheria toxin sensitivity. , 1994, The EMBO journal.

[65]  V. Ghetie,et al.  Phase I Trial of an Anti‐CD19 Deglycosylated Ricin A Chain Immunotoxin in Non‐Hodgkin's Lymphoma: Effect of an Intensive Schedule of Administration , 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[66]  V. Calcaterra,et al.  Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity. , 1999, Blood.

[67]  I. Pastan,et al.  Treatment of advanced solid tumors with immunotoxin LMB–1: An antibody linked to Pseudomonas exotoxin , 1996, Nature Medicine.

[68]  P. Linsley,et al.  Prevention of immunotoxin-induced immunogenicity by coadministration with CTLA4Ig enhances antitumor efficacy. , 1997, Journal of immunology.

[69]  D. Eisenberg,et al.  Dynamic transitions of the transmembrane domain of diphtheria toxin: disulfide trapping and fluorescence proximity studies. , 1994, Biochemistry.

[70]  I. Pastan,et al.  B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[71]  J. Uhr,et al.  Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites. , 1991, Cancer research.

[72]  L. Montanaro,et al.  High-pressure-liquid-chromatographic and fluorimetric methods for the determination of adenine released from ribosomes by ricin and gelonin. , 1989, The Biochemical journal.

[73]  I. Pastan,et al.  Human neurological cancer cells express interleukin‐4 (IL‐4) receptors which are targets for the toxic effects of IL4‐pseudomonas exotoxin chimeric protein , 1994, International journal of cancer.

[74]  I. Pastan,et al.  Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[75]  R. Collins,et al.  A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. , 1996, Blood.

[76]  H. Deeg,et al.  Evaluation of a CD5-specific immunotoxin for treatment of acute graft- versus-host disease after allogeneic marrow transplantation , 1996 .

[77]  V. Diehl,et al.  A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. , 1997, Blood.

[78]  D. Esseltine,et al.  Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  I. Pastan,et al.  A circularly permuted recombinant interleukin 4 toxin with increased activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[80]  I. Pastan,et al.  Purification and characterization of IL6-PE4E, a recombinant fusion of interleukin 6 with Pseudomonas exotoxin. , 1993, Bioconjugate chemistry.

[81]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  P. Wen,et al.  Use of the immunotoxin N901‐blocked ricin in patients with small‐cell lung cancer , 1994, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[83]  J. Ritz,et al.  Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. , 1992, Blood.

[84]  S. Erlandsen,et al.  An in vitro model for toxin-mediated vascular leak syndrome: ricin toxin A chain increases the permeability of human endothelial cell monolayers. , 1997, Blood.

[85]  A. Tulpule,et al.  Immunotoxin combined with chemotherapy for patients with AIDS‐related non‐Hodgkin's lymphoma , 1998, Cancer.

[86]  J. Uhr,et al.  Purification and properties of immunotoxins containing one vs. two deglycosylated ricin A chains. , 1993, Journal of immunological methods.

[87]  E. Jaffe,et al.  Complete Sustained Response of a Refractory, Post-Transplantation, Large B-Cell Lymphoma to an Anti-CD22 Immunotoxin , 1997, Annals of Internal Medicine.

[88]  V. Diehl,et al.  Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma. , 1998, Leukemia & lymphoma.

[89]  R. S. Watson,et al.  Cellular processing of the interleukin-2 fusion toxin DAB486-IL-2 and efficient delivery of diphtheria fragment A to the cytosol of target cells requires Arg194. , 1990, The Journal of biological chemistry.

[90]  R. Mera,et al.  Aggressive administration of recombinant oncotoxin AR209 (anti-ErbB-2) in athymic nude mice implanted with orthotopic human non-small cell lung tumours. , 1998, European journal of cancer.

[91]  W. Evans,et al.  In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[92]  I. Pastan,et al.  Characterization of monoclonal antibodies B1 and B3 that react with mucinous adenocarcinomas. , 1991, Cancer research.

[93]  F. Studier,et al.  Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. , 1986, Journal of molecular biology.

[94]  I. Pastan,et al.  Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. , 1996, Cancer research.

[95]  M. Willingham,et al.  Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. , 1997, Leukemia & lymphoma.